PledPharma AB   Report issue

For profit Phase 2 Phase 3
Founded: Stockholm Sweden (2006)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2008
NCT00671996
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

PledPharma AB

Active Ingredients

Drugs in Phase 3 Trials (1)

calmangafodipir (3 trials)

Drugs in Phase 2 Trials (1)

mangafodipir trisodium (teslascan) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 3)

Drug Overdose (Phase 1)

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

Peripheral Nervous System Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 2